A Korean Post-Marketing Surveillance Study of Dolutegravir Single-Agent Tablets in Patients with HIV-1
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The integrase strand transfer inhibitor dolutegravir has been indicated in Korea since 2014 for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. This regulatory post-marketing surveillance (PMS) study evaluated the real-life safety and effectiveness of dolutegravir in patients with HIV-1 in clinical practice in Korea. Materials and methods: This open-label PMS study examined data from consecutive patients (aged ≥12 years) with HIV-1 infection receiving dolutegravir according to locally approved prescribing information; treatment-naïve and treatment-experienced patients were permitted. Data regarding patient demographics, medical history, clinical characteristics, medications (HIV-related and concomitant), and comorbidities were extracted from patient records over a 1-year treatment period. Outcomes included the safety of dolutegravir (primary endpoint) and real-life effectiveness according to the Physician Global Assessment (PGA) and the proportion of patients with plasma HIV-1 RNA count <50 copies/mL at 48 weeks. Results: Of 147 patients treated with dolutegravir at 18 centers in Korea (August 2014 - August 2020), 139 were eligible for the safety analyses and 75 for effectiveness analyses. Patients (mean age 47 years) were mostly male (92.8%) and received dolutegravir in combination with nucleoside reverse transcriptase inhibitor (70.5%) or protease inhibitors (21.6%). Adverse events (AEs) (n = 179 in total) were mostly mild in severity, with the most common being nasopharyngitis (5.0%), dyspepsia (5.0%), pruritus (4.3%), and rash (4.3%). Of 16 adverse drug reactions (ADRs), the most frequent were rash, diarrhea, headache, insomnia, and somnolence (1.4% each). Of 2 serious ADRs, only 1 (gastroenteritis) was unexpected, and both resolved. The risk of experiencing an AE while receiving dolutegravir appeared to be especially increased in patients receiving concomitant medications for other conditions. Dolutegravir effectively suppressed HIV-1 (93.3% of patients had plasma HIV-1 RNA <50 copies/mL), and 100% of patients showed symptom improvement based on physician global assessment. Conclusion: Results of this PMS study showed that dolutegravir administered as highly active antiretroviral therapy was well tolerated and effective in patients with HIV-1 infection.
Abstract
Background: The integrase strand transfer inhibitor dolutegravir has been indicated in Korea since 2014 for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral agents. This regulatory post-marketing surveillance (PMS) study evaluated the real-life safety and effectiveness of dolutegravir in patients with HIV-1 in clinical practice in Korea. Materials and methods: This open-label PMS study examined data from consecutive patients (aged ≥12 years) with HIV-1 infection receiving dolutegravir according to locally approved prescribing information; treatment-naïve and treatment-experienced patients were permitted. Data regarding patient demographics, medical history, clinical characteristics, medications (HIV-related and concomitant), and comorbidities were extracted from patient records over a 1-year treatment period. Outcomes included the safety of dolutegravir (primary endpoint) and real-life effectiveness according to the Physician Global Assessment (PGA) and the proportion of patients with plasma HIV-1 RNA count <50 copies/mL at 48 weeks. Results: Of 147 patients treated with dolutegravir at 18 centers in Korea (August 2014 - August 2020), 139 were eligible for the safety analyses and 75 for effectiveness analyses. Patients (mean age 47 years) were mostly male (92.8%) and received dolutegravir in combination with nucleoside reverse transcriptase inhibitor (70.5%) or protease inhibitors (21.6%). Adverse events (AEs) (n = 179 in total) were mostly mild in severity, with the most common being nasopharyngitis (5.0%), dyspepsia (5.0%), pruritus (4.3%), and rash (4.3%). Of 16 adverse drug reactions (ADRs), the most frequent were rash, diarrhea, headache, insomnia, and somnolence (1.4% each). Of 2 serious ADRs, only 1 (gastroenteritis) was unexpected, and both resolved. The risk of experiencing an AE while receiving dolutegravir appeared to be especially increased in patients receiving concomitant medications for other conditions. Dolutegravir effectively suppressed HIV-1 (93.3% of patients had plasma HIV-1 RNA <50 copies/mL), and 100% of patients showed symptom improvement based on physician global assessment. Conclusion: Results of this PMS study showed that dolutegravir administered as highly active antiretroviral therapy was well tolerated and effective in patients with HIV-1 infection.
참고문헌 (20)
- Eun Young Lee, "Estimation of the Number of HIV Infections and Time to Diagnosis in the Korea", Journal of Korean Medical Science, 35(6), pp.1~10 (2020), 대한의학회[DOI]
- Kim June Myung, "History of Acquired Immune Deficiency Syndrome in Korea", Infection and Chemotherapy, 52(2), pp.234~244 (2020), 대한감염학회[DOI]
- Myeongsu Yoo, "Current Status of the Estimation on the Number of People Who Living with HIV and the Rate of Undiagnosed Cases", Journal of Bacteriology and Virology, 50(3), pp.150~157 (2020), 대한미생물학회[DOI]
- 최윤수, "Epidemiological characteristics of HIV infected Korean: Korea HIV", AIDS Cohort Study, 2019, pp.41, 1~9[DOI]
- Kee MK, "Influence of anonymous HIV testing on national HIV surveillance in the Republic of Korea(2000 to 2015) : a retrospective analysis", BMC Public Health, 19, pp.1563~ (2019)
- Sohn A, "Knowledge, attitudes, and sexual behaviors in HIV", AIDS and predictors affecting condom use among men who have sex with men in South Korea, 2012, pp.3, 156~164
- 이선희, "Trends of Mortality and Cause of Death among HIV-Infected Patients in Korea, 1990-2011", Journal of Korean Medical Science, 28(1), pp.67~73 (2013), 대한의학회
- Hajimahdi Z, "Progress in HIV-1 integrase inhibitors : A review of their chemical structure diversity", Iran J Pharm Res, 15, pp.595~628 (2016)
- The Korean Society for AIDS, "The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV", AIDS in HIV-Infected Koreans, 2019, pp.51(1), 77~88[DOI]
- "TBK tablets 50mg (dolutegravir sodium)"[URL]
- Boffito M, "Perspectives on the barrier to resistance for dolutegravir + lamivudine, a two-drug antiretroviral therapy for HIV-1 infection", AIDS Res Hum Retroviruses, 36, pp.13~18 (2020)
- Hongo H, "Safety and effectiveness analysis of dolutegravir in patients with HIV-1 : interim report of post-marketing surveillance in Japan", Adv Ther, 38, pp.4480~4504 (2021)
- Cahn P, "Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study", Lancet, 382, pp.700~708 (2013)
- Castagna A, "Dolutegravir in antiretroviral-experienced patients with raltegravir-and", or elvitegravir-resistant HIV-1 : 24-week results of the phase III VIKING-3 study, 2014, pp.210, 354~362
- Eron JJ, "Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection : 24-week results of the VIKING Study", J Infect Dis, 207, pp.740~748 (2013)
- Molina JM, "Once-daily dolutegravir versus darunavir plus ritonavir for treatmentnaive adults with HIV-1 infection(FLAMINGO) : 96 week results from a randomised, open-label, phase 3b study", Lancet HIV, 2, pp.e127~36 (2015)
- RaffiF, "Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection(SPRING-2 study) : 96 week results from a randomised, double-blind, non-inferiority trial", Lancet Infect Dis, 13, pp.927~935 (2013)
- Stellbrink HJ, "Dolutegravir in antiretroviral-naive adults with HIV-1 : 96-week results from a randomized dose-ranging study", AIDS, 27, pp.1771~1778 (2013)
- KheloufiF, "Neuropsychiatric events and dolutegravir in HIV patients : a worldwide issue involving a class effect", AIDS, 31, pp.1775~1777 (2017)
- 김진, "Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens", Infection and Chemotherapy, 54(3), pp.419~432 (2022), 대한감염학회[DOI]